Research Paper Volume 12, Issue 5 pp 4547—4557

Figure 1. ARV-825 inhibits human thyroid carcinoma cell viability, proliferation and migration. TPC-1 cells (A–D), the primary human thyroid carcinoma cells (“C1”/“C2”, E–G) or the primary human thyroid epithelial cells (“E1”/“E2”, E–G) were left untreated (“Ctrl”, same for all Figures) or treated with ARV-825 (5-250 nM). Cells were further cultured in complete medium for indicated time periods, cell viability (MTT OD, A and E), colony formation (B), cell proliferation (EdU incorporation, C and F) and migration (“Transwell” assays, D and G) were tested. Data were presented as mean ± standard deviation (SD, n=5) (same for all Figures). *p < 0.05 vs. “Ctrl” group. ***p < 0.001 vs. “Ctrl” group. The experiments were repeated three times, with similar results obtained. Bar= 100 μm (C and D).